Disease Landscape and Forecast Insights

The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) plus endocrine therapy are entrenched first-line…

The treatment landscape for advanced HR-positive / HER2-negative breast cancer is continually evolving. CDK4/6 inhibitors, such as Pfizer’s Ibrance and Novartis’s Kisqali, are commonly used…

The treatment of breast cancer is associated with strong commercial opportunity because of the disease’s high incidence, long treatment durations, and multiple lines of therapy. The CDK4/6…

Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…

Breast cancer is the most prevalent malignancy in women in China. Chemotherapy was the mainstay of treatment, but China now has access to several cutting-edge premium-priced targeted therapies (e.g…

Hormone receptor (HR)-positive / HER2-negative breast cancer is the most prevalent breast cancer subtype. Targeted therapies aimed at CDK4/6 inhibition (Pfizer’s Ibrance, Novartis’s Kisqali,…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to…

In the last decades, markedly improved survival benefit has been achieved in the treatment of advanced or metastatic HER2-positive breast cancer. Effective HER2-targeted drugs such as Herceptin,…

Breast cancer is the most commonly diagnosed cancer in women in China. The disease has been managed primarily through chemotherapy in China, but several novel, premium-priced targeted therapies—…

The high incidence, long treatment duration, and multiple lines of therapy in the treatment of breast cancer represent strong commercial opportunity for drug development. The CDK4/6 inhibitors (…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to…

Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…